Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | PNMT | P11086 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373062 | 0.80 | CYP3A4 (0.41) | CYP3A4PNMTCYP1A2CYP2D6NFKB1 | |
| SCHEMBL18891265 | 0.79 | CYP3A4 (0.52) | CYP3A4PNMTCYP1A2CYP2D6NFKB1 | |
| SCHEMBL158333 | 0.79 | PNMT (1.00) | CYP3A4PNMTCYP1A2CYP2D6NFKB1 | |
| SCHEMBL12061474 | 0.79 | CYP3A4 (0.52) | CYP3A4PNMTCYP1A2CYP2D6NFKB1 | |
| SCHEMBL8207165 | 0.79 | PNMT (1.00) | CYP3A4PNMTCYP1A2CYP2D6NFKB1 | |
| SCHEMBL8207792 | 0.79 | PNMT (1.00) | CYP3A4PNMTCYP1A2CYP2D6NFKB1 | |
| SCHEMBL11501879 | 0.78 | CYP3A4 (0.40) | CYP3A4PNMTCYP1A2CYP2D6NFKB1 | |
| SCHEMBL17069825 | 0.77 | CYP1A2 (0.50) | CYP3A4PNMTCYP1A2CYP2D6NFKB1 | |
| SCHEMBL17069824 | 0.77 | CYP1A2 (0.50) | CYP3A4PNMTCYP1A2CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL1321451 | 0.77 | LMNA (1.00) | CYP3A4PNMTCYP1A2CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-11077100-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | RAQUALIA PHARMA INC. (JP) | 2021-08-03 | — | — | US | disclosed |
| US-20210085667-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20200405706-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405706-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | CYP3A4 752/4885PNMT 2406/4885CYP1A2 758/4885 |
| US-11077100-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | CYP3A4 752/4885PNMT 2406/4885CYP1A2 758/4885 |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | CYP3A4 752/4885PNMT 2406/4885CYP1A2 758/4885 |
| US-20210085667-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | CYP3A4 752/4885PNMT 2406/4885CYP1A2 758/4885 |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | CYP3A4 717/4885PNMT 446/4885CYP1A2 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.